文献速递糖尿病肥胖与代谢综合征

妊娠期糖尿病使用二甲双胍后的产后心血管代谢健康:EMERGE试验的二次分析

Postnatal Cardiometabolic Health After Metformin Use in Gestational Diabetes: A Secondary Analysis of the EMERGE Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

EMERGE双盲安慰剂对照试验的二次分析纳入478例妊娠期糖尿病孕妇,随机1:1在诊断时接受二甲双胍或安慰剂,随访至产后12±4周。二甲双胍组产后体重和BMI显著低于安慰剂组,但体重变化、糖尿病前期或糖尿病比例、胰岛素抵抗、血压和血脂均无差异。结论认为早期二甲双胍虽改善孕期体重增加和胰岛素使用,但未影响产后早期重要心血管代谢参数。

要点

  • 二甲双胍组产后体重79.5±15.9 kg,显著低于安慰剂组82.6±16.9 kg(P=.04)。
  • 二甲双胍组产后BMI 29.3[5.6],显著低于安慰剂组30.5[5.4](P=.018)。
  • 两组从随机化至产后12周的体重变化、糖尿病前期或糖尿病比例、胰岛素抵抗、血压和血脂均无差异。

核心结论

  • 妊娠期糖尿病早期使用二甲双胍未影响产后早期重要心血管代谢参数,尽管孕期体重增加和胰岛素使用有显著获益。

研究设计与样本

  • EMERGE为双盲、安慰剂对照试验,妊娠期糖尿病诊断时按1:1随机分配至安慰剂或二甲双胍,从随机化随访至产后12±4周。
  • 共478例妊娠可供产后母体评估,二甲双胍组237例,安慰剂组241例。

主要发现

  • 尽管随机化时体重和BMI相似,二甲双胍组产后访视时体重显著低于安慰剂组(79.5±15.9 vs 82.6±16.9 kg;P=.04)。
  • 二甲双胍组产后BMI显著低于安慰剂组(29.3[5.6] vs 30.5[5.4];P=.018)。
  • 从随机化至产后12周的体重变化,二甲双胍组与安慰剂组无差异。
  • 队列中29%(n=139)符合糖尿病前期或糖尿病标准,二甲双胍未显示积极影响。
  • 两组在胰岛素抵抗、血压或血脂测量上无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Women with gestational diabetes mellitus (GDM) display adverse lifetime cardiometabolic health. We examined whether early metformin in GDM could impact cardiometabolic risk factors postpartum. METHODS: EMERGE, a double-blind, placebo-controlled trial, randomized pregnancies 1:1 to placebo or metformin at GDM diagnosis and followed participants from randomization until 12 ± 4 weeks postpartum. In total, 478 pregnancies were available for postpartum maternal assessment, 237 and 241 assigned to metformin and placebo respectively. Weight (kg), body mass index (BMI) (kg/m2), waist circumference (cm), and blood pressure (mmHg) were measured, infant feeding method documented, and blood specimens drawn for a 75-gram oral glucose tolerance test, fasting insulin, C-peptide, and lipid analysis. RESULTS: Despite similar weight and BMI at trial randomization, participants receiving metformin had significantly lower weight (79.5 ± 15.9 vs 82.6 ± 16.9 kg; P = .04) and BMI (29.3 [5.6] vs 30.5 [5.4]; P = .018) at the postpartum visit. However, no difference in weight change from randomization to 12 weeks postpartum was observed between metformin and placebo groups. Overall, 29% (n = 139) of the cohort met criteria for prediabetes or diabetes, with no positive impact with metformin. There were also no differences in measurements of insulin resistance, blood pressure, or lipids between groups. CONCLUSION: Early metformin use in GDM did not impact important cardiometabolic parameters in the early postpartum period despite significant benefits in weight gain and insulin use in pregnancy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Dunne F, Newman C, Alvarez-Iglesias A, et al. Postnatal Cardiometabolic Health After Metformin Use in Gestational Diabetes: A Secondary Analysis of the EMERGE Trial. J Clin Endocrinol Metab. 2025. PMID: 39056256. doi:10.1210/clinem/dgae522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。